We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVMD Stock Hits a Record High on Rumored Takeover Interest
Read MoreHide Full Article
Key Takeaways
RVMD stock surged nearly 29% after a WSJ report cited possible AbbVie acquisition interest.
ABBV later denied takeover talks, though the report said a deal could value RVMD at $20B or more.
Revolution Medicines develops RAS(ON) cancer drugs, with lead candidate daraxonrasib in late-stage studies.
Shares of Revolution Medicines (RVMD - Free Report) rose nearly 29% on Wednesday following a report issued by the Wall Street Journal (WSJ), as cited in a Yahoo Finance article, which stated that pharma giant AbbVie (ABBV - Free Report) was interested in acquiring the company.
However, AbbVie denied this speculation in an emailed statement to Reuters, stating that it "is not in discussions with Revolution Medicines."
While the article claimed that WSJ could not learn the exact terms of the deal, it did state that AbbVie was nearing a deal that could value Revolution Medicines at around $20 billion or more.
California-based Revolution Medicines is a clinical-stage company developing multiple novel drugs that target the active, GTP-bound form (or ON form) of RAS proteins, which the company refers to as RAS(ON). Its lead pipeline drug is daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor designed to target all three major RAS mutation hotspot positions (G12, G13 and Q61). The drug is being evaluated in separate late-stage studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
RVMD is also developing mutant-selective inhibitors like elironrasib and zoldonrasib that are designed to suppress the growth of specific RAS-bearing cancer cells. Both drugs are being evaluated either as monotherapy or in combination with other anti-cancer therapies in separate early-stage studies across solid tumor indications.
RVMD Stock Price Performance
Post the release of the WSJ article, shares of Revolution Medicines hit an all-time high of $105 per share. In fact, shares of the company’s peers, like Erasca and Verastem Oncology, which are also developing RAS inhibitors, surged 42% and 11%, respectively, on Wednesday.
In the past year, RVMD’s stock has soared 131% compared with the industry’s 17% growth.
Image Source: Zacks Investment Research
Recent M&A Transactions in the Pharma Space
After a muted start to 2025, Big Pharma has returned to the mergers and acquisitions (M&A) arena in recent months. This rebound has been supported by major drugmakers signing drug pricing agreements with the Trump administration, which eased concerns over potential tariff-related impacts and removed a key policy overhang.
Although it has just been a week since the start of 2026, Big Pharma continues to pursue strategic assets in key growth areas.Earlier this week, large-cap pharma companies Amgen (AMGN - Free Report) and Eli Lilly (LLY - Free Report) announced separate acquisition deals.
Amgen announced it has acquired U.K.-based private biotech company Dark Blue Therapeutics for approximately $840 million. This acquisition aims to strengthen Amgen’s oncology pipeline by adding Dark Blue’s preclinical, targeted small-molecule degrader, which degrades two proteins (MLLT1/3) that drive specific types of acute myeloid leukemia (AML). These differentiated molecules have shown promising anti-cancer activity in pre-clinical studies and are designed to treat certain types of AML.
In parallel, Eli Lilly recently signed a deal to buy clinical-stage biotech Ventyx Biosciences for a total value of about $1.2 billion. Once this acquisition is completed, Lilly intends to add Ventyx's clinical pipeline of small molecule oral therapies that are designed to treat inflammation across a broad range of diseases, including cardiometabolic disorders, neurodegenerative diseases and inflammatory disorders.
Image: Bigstock
RVMD Stock Hits a Record High on Rumored Takeover Interest
Key Takeaways
Shares of Revolution Medicines (RVMD - Free Report) rose nearly 29% on Wednesday following a report issued by the Wall Street Journal (WSJ), as cited in a Yahoo Finance article, which stated that pharma giant AbbVie (ABBV - Free Report) was interested in acquiring the company.
However, AbbVie denied this speculation in an emailed statement to Reuters, stating that it "is not in discussions with Revolution Medicines."
While the article claimed that WSJ could not learn the exact terms of the deal, it did state that AbbVie was nearing a deal that could value Revolution Medicines at around $20 billion or more.
California-based Revolution Medicines is a clinical-stage company developing multiple novel drugs that target the active, GTP-bound form (or ON form) of RAS proteins, which the company refers to as RAS(ON). Its lead pipeline drug is daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor designed to target all three major RAS mutation hotspot positions (G12, G13 and Q61). The drug is being evaluated in separate late-stage studies for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
RVMD is also developing mutant-selective inhibitors like elironrasib and zoldonrasib that are designed to suppress the growth of specific RAS-bearing cancer cells. Both drugs are being evaluated either as monotherapy or in combination with other anti-cancer therapies in separate early-stage studies across solid tumor indications.
RVMD Stock Price Performance
Post the release of the WSJ article, shares of Revolution Medicines hit an all-time high of $105 per share. In fact, shares of the company’s peers, like Erasca and Verastem Oncology, which are also developing RAS inhibitors, surged 42% and 11%, respectively, on Wednesday.
In the past year, RVMD’s stock has soared 131% compared with the industry’s 17% growth.
Image Source: Zacks Investment Research
Recent M&A Transactions in the Pharma Space
After a muted start to 2025, Big Pharma has returned to the mergers and acquisitions (M&A) arena in recent months. This rebound has been supported by major drugmakers signing drug pricing agreements with the Trump administration, which eased concerns over potential tariff-related impacts and removed a key policy overhang.
Although it has just been a week since the start of 2026, Big Pharma continues to pursue strategic assets in key growth areas.Earlier this week, large-cap pharma companies Amgen (AMGN - Free Report) and Eli Lilly (LLY - Free Report) announced separate acquisition deals.
Amgen announced it has acquired U.K.-based private biotech company Dark Blue Therapeutics for approximately $840 million. This acquisition aims to strengthen Amgen’s oncology pipeline by adding Dark Blue’s preclinical, targeted small-molecule degrader, which degrades two proteins (MLLT1/3) that drive specific types of acute myeloid leukemia (AML). These differentiated molecules have shown promising anti-cancer activity in pre-clinical studies and are designed to treat certain types of AML.
In parallel, Eli Lilly recently signed a deal to buy clinical-stage biotech Ventyx Biosciences for a total value of about $1.2 billion. Once this acquisition is completed, Lilly intends to add Ventyx's clinical pipeline of small molecule oral therapies that are designed to treat inflammation across a broad range of diseases, including cardiometabolic disorders, neurodegenerative diseases and inflammatory disorders.
Revolution Medicines, Inc. Price
Revolution Medicines, Inc. price | Revolution Medicines, Inc. Quote
RVMD’s Zacks Rank
Revolution Medicines currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.